Welcome to our dedicated page for Cameco SEC filings (Ticker: CCJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cameco Corporation's SEC filings document a Canadian nuclear energy company that reports to U.S. regulators primarily through Form 6-K current reports and Form 40-F annual materials. The record includes IFRS financial statements, management's discussion and analysis, annual reports, interim results, and disclosures for the Uranium, Fuel Services, and Westinghouse segments.
Company filings also cover proxy materials, annual meeting notices, director election voting results, executive-compensation advisory matters, auditor appointments, officer certifications, registration-statement incorporations, and corporate-governance documents such as the Code of Conduct and Ethics. Additional exhibits address long-term uranium supply agreements and supply-chain compliance reporting, including the Modern Slavery Report for Cameco and Cameco Fuel Manufacturing Inc.
Cameco Corporation filed a Form 6-K to furnish its updated Code of Conduct and Ethics, which applies to all employees, senior executives and board directors worldwide. The Code emphasizes integrity, legal compliance and safety, covering insider trading, anti-corruption, competition law, imports/exports of nuclear materials, conflicts of interest, confidentiality, data privacy and protection of intellectual property.
It sets expectations for respectful, inclusive workplaces, human rights, environmental protection, community engagement and fair dealing with customers, suppliers and competitors. The document describes internal controls for accurate financial reporting and continuous disclosure, outlines how to report concerns (including an independent 24/7 Ethics Hotline), and confirms strong non‑retaliation protections. Governance of the Code rests with senior officers and board committees, with annual certifications and defined processes for investigating violations and approving any waivers.
Cameco Corporation has a notice to sell 25,000 common shares. The planned sale is listed through broker Solium Financial Inc. on the NYSE, with an approximate sale date of 01/07/2026 and an aggregate market value of 2,598,500.00. These 25,000 shares were acquired on the same date via a stock option exercise paid in cash.
During the past three months, Timothy S. Gitzel sold 50,000 common shares on 01/02/2026 for gross proceeds of 4,928,000.00 and another 50,000 shares on 12/19/2025 for 4,499,500.00. Shares outstanding were 435,457,978; this is a baseline figure, not the amount being sold.
A shareholder filed a Rule 144 notice to sell 1,000 common shares of the issuer through broker Solium Financial Inc. on or about 01/05/2026 on the NYSE. The filing lists an aggregate market value of 100170.00 for these shares and notes that 435457978 shares were outstanding. The shares to be sold were acquired on 03/03/2023 as a vesting of a long-term incentive (LTI) award, with payment made in cash on the same date.
By signing the notice, the selling shareholder represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed, and is reminded that intentional misstatements or omissions can constitute federal criminal violations.
A holder of CCJ common shares filed a Rule 144 notice to sell 4,000 common shares on the NYSE, with an aggregate market value of $400,680.00. The filing lists 435,457,978 shares of this class as outstanding, which provides context for the size of the planned sale. The shares to be sold were acquired on 03/03/2023 through the vesting of a long-term incentive (LTI) award, and the payment method is described as cash. The approximate date of sale is given as 01/05/2026, indicating an intention to dispose of these shares on or around that date under Rule 144.
A shareholder has filed a notice of proposed sale of Cameco Corporation common shares under Rule 144. The filing covers the planned sale of 50,000 common shares, with an indicated aggregate market value of $4,928,000.00. These shares are to be sold on the NYSE through Solium Financial Inc. on or about 01/02/2026. The issuer had 435,457,158 common shares outstanding at the time referenced.
The 50,000 shares to be sold were acquired on 01/02/2026 via a stock option exercise from Cameco Corporation, paid in cash. The filing also notes that the same seller, Timothy S. Gitzel, sold 50,000 common shares on 12/19/2025 for gross proceeds of $4,499,500.00 during the prior three-month period.
Cameco Corporation shareholder plans NYSE sale after option exercise
A shareholder of Cameco Corporation has filed notice of a planned sale of 50,000 common shares through broker Solium Financial Inc. on the NYSE, with an approximate sale date of 12/19/2025. The filing lists an aggregate market value of $4,499,500.00 for the shares to be sold. These shares were acquired on 12/19/2025 via a stock option exercise from Cameco Corporation, paid in cash for 50,000 shares. The filing notes that 435,407,158 common shares were outstanding, providing context for the size of the planned sale.
Cameco Corporation (CCJ) filed a Form 144 disclosing a proposed sale of 19,460 common shares with an aggregate market value of $1,680,000. The filing shows the shares represent part of the issuer's outstanding common stock of 435,387,448 shares and names the intended sale date as 09/15/2025 on the NYSE. The shares were acquired on 09/15/2025 through a stock option exercise from Cameco Corporation and payment was in cash. The filer reports no securities sold during the past three months and includes the standard attestation that the seller is not aware of undisclosed material adverse information.
Cameco Corporation (CCJ) filed a Form 144 disclosing a proposed sale of 19,460 common shares with an aggregate market value of $1,680,000. The filing shows the shares represent part of the issuer's outstanding common stock of 435,387,448 shares and names the intended sale date as 09/15/2025 on the NYSE. The shares were acquired on 09/15/2025 through a stock option exercise from Cameco Corporation and payment was in cash. The filer reports no securities sold during the past three months and includes the standard attestation that the seller is not aware of undisclosed material adverse information.